Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 15Fallopian Tube Neoplasms 13Lung Neoplasms 11Melanoma 8Colorectal Neoplasms 8Glioblastoma 7Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Brain Neoplasms 4Rectal Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Oligodendroglioma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, B-Cell 2Lymphoma 2

Interventions

tremelimumab 1telisotuzumab vedotin 1durvalumab 1Immunoglobulin G 1Disulfides 12-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrent Squamous Cell Lung Carcinoma × Disulfides × Clear all
NCT03373760 2023-06-09

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

SWOG Cancer Research Network

Phase 2 Completed
67 enrolled 17 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡